Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Docetaxel With or Without PSA-TRICOM Vaccine in Metastatic CRPC
NCT01145508Phase 2Terminated
- Sponsor
- National Cancer Institute
- Start
- Aug 2010
- Primary completion
- Oct 2012
- Modality
- Viral Vectors, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of rilimogene galvacirepvec in metastatic castration-resistant prostate cancer (mCRPC), sponsored by National Cancer Institute. Started Aug 2010; status: terminated.
02
Drugs
rilimogene galvacirepvec
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT01145508.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01145508.